This article is more than 5 years old. Information may no longer be current.

Fixed combination glaucoma drug is safe, well tolerated, clinician says

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — A fixed combination of travoprost and timolol was found to be safe and well tolerated and to reduce mean IOP more than either of its individual components.

Howard Barneby, MD, presented the study of Alcon’s Extravan (travoprost 0.004%, timolol 0.5%) here at the American Academy of Ophthalmology meeting. The study compared Extravan to Travatan (travoprost, Alcon) alone or timolol 0.5% alone.

Patients were randomized to one of three regimens for a 6-month period: 85 patients received the fixed combination in the morning plus vehicle in the evening; 86 patients received the vehicle in the morning and travoprost in the evening; and 92 patients received timolol in both the morning and evening.

The study found that mean IOP reduction following treatment with Extravan was greater than with either travoprost alone (up to 2.2 mm Hg difference) or timolol alone (up to 3 mm Hg difference).

“The advantages of this drug,” Dr. Barneby said, “are that it proves IOP-lowering efficacy, its safety profile is similar to single agents and it is convenient.”